Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COEP Coeptis Therapeutics	$11.18 +1.1%	$9.45	$2.31 ▼ $13.70	$38.86M	-0.59	57,368 shs	54,489 shs
LVTX LAVA Therapeutics	$1.53 +0.7%	$1.39	$0.85 ▼ $2.09	$39.98M	0.5	152,872 shs	22,972 shs
RNAZ TransCode Therapeutics	$11.51 +4.7%	$9.08	$6.15 ▼ $739.20	$9.16M	1.46	251,534 shs	13,803 shs
SLGL Sol-Gel Technologies	$15.25 -5.9%	$9.19	$3.61 ▼ $16.89	$45.14M	1.21	16,975 shs	30,002 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COEP Coeptis Therapeutics	-0.90%	-4.24%	+17.52%	+12.28%	+173.76%
LVTX LAVA Therapeutics	-0.65%	+3.40%	+11.76%	+21.60%	-14.12%
RNAZ TransCode Therapeutics	+5.77%	-3.60%	+26.47%	+13.05%	-99.86%
SLGL Sol-Gel Technologies	+0.03%	+19.19%	+96.50%	+111.29%	+337.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COEP Coeptis Therapeutics	0.1947 of 5 stars	0.0	3.0	0.0	1.7	0.0
LVTX LAVA Therapeutics	1.8982 of 5 stars	3.0	5.0	2.1	0.0	0.0
RNAZ TransCode Therapeutics	1.9721 of 5 stars	3.5	4.0	0.6	0.0	0.6
SLGL Sol-Gel Technologies	1.9524 of 5 stars	3.5	3.0	1.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
LVTX LAVA Therapeutics	2.00	Hold	$2.69	75.49% Upside
RNAZ TransCode Therapeutics	3.00	Buy	$280.00	2,332.67% Upside
SLGL Sol-Gel Technologies	3.00	Buy	$40.00	162.30% Upside

Current Analyst Ratings Breakdown

Latest RNAZ, COEP, LVTX, and SLGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$1.50 ➝ $1.24
8/5/2025	LVTX LAVA Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$3.00 ➝ $1.50
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	$1.61 per share	N/A
LVTX LAVA Therapeutics	$11.98M	3.36	N/A	N/A	$1.06 per share	1.44
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	($54.96) per share	N/A
SLGL Sol-Gel Technologies	$11.54M	3.69	N/A	N/A	$10.36 per share	1.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-282.39%	-127.23%	N/A
LVTX LAVA Therapeutics	-$25.11M	-$1.04	N/A	N/A	N/A	N/A	-86.38%	-34.12%	8/19/2025 (Estimated)
RNAZ TransCode Therapeutics	-$16.75M	N/A	0.00	N/A	N/A	N/A	-578.88%	-222.61%	8/13/2025 (Estimated)
SLGL Sol-Gel Technologies	-$10.58M	-$4.70	N/A	N/A	N/A	-107.78%	-43.98%	-35.28%	8/15/2025 (Estimated)

Latest RNAZ, COEP, LVTX, and SLGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q2 2025	LVTX LAVA Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million
5/21/2025	Q4 2024	RNAZ TransCode Therapeutics	-$2.00	-$0.60	+$1.40	-$2.51	$0.30 million	N/A
5/14/2025	Q1 2025	COEP Coeptis Therapeutics	N/A	-$1.11	N/A	-$1.11	N/A	N/A
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COEP Coeptis Therapeutics	0.02	0.82	0.82
LVTX LAVA Therapeutics	N/A	6.73	6.73
RNAZ TransCode Therapeutics	N/A	5.20	5.20
SLGL Sol-Gel Technologies	N/A	5.12	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COEP Coeptis Therapeutics	13.88%
LVTX LAVA Therapeutics	N/A
RNAZ TransCode Therapeutics	N/A
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
COEP Coeptis Therapeutics	24.25%
LVTX LAVA Therapeutics	9.50%
RNAZ TransCode Therapeutics	0.01%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COEP Coeptis Therapeutics	2	3.51 million	2.66 million	Not Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
RNAZ TransCode Therapeutics	9	830,000	834,000	Not Optionable
SLGL Sol-Gel Technologies	50	2.79 million	933,000	Optionable

RNAZ, COEP, LVTX, and SLGL Headlines

Recent News About These Companies

Sol-Gel Technologies Ltd. (SLGL) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Sol-Gel Technologies Ltd. (SLGL) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

SLGL Sol-Gel Technologies Ltd. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Sol-Gel Technologies Ltd

June 21, 2025 | morningstar.comM

Sol Gel Tech Stock Price History

June 1, 2025 | investing.com

Sol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | finanznachrichten.de

Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic

May 23, 2025 | msn.com

Sol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D Expenses

May 23, 2025 | quiverquant.comQ

Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | globenewswire.com

Insider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of Shares

May 3, 2025 | uk.finance.yahoo.com

This Sol-Gel Technologies Insider Increased Their Holding In The Last Year

May 2, 2025 | finance.yahoo.com

Sol-Gel Announces Reverse Share Split

May 1, 2025 | globenewswire.com

Sol-Gel, Mayne Pharma enter product purchase agreement

April 17, 2025 | markets.businessinsider.com

Sol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.

April 17, 2025 | finanznachrichten.de

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

April 17, 2025 | globenewswire.com

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

April 7, 2025 | globenewswire.com

Sol-Gel Technologies Approves Reverse Share Split and Compensation Policy Renewal

April 1, 2025 | tipranks.com

SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

February 25, 2025 | zacks.com

Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?

February 7, 2025 | finance.yahoo.com

Sol Gel Technologies Ltd (SLGL) Stock Trading Recap

December 26, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, COEP, LVTX, and SLGL Company Descriptions

Coeptis Therapeutics NASDAQ:COEP

$11.18 +0.12 (+1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$11.16 -0.03 (-0.22%)

As of 04:10 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

LAVA Therapeutics NASDAQ:LVTX

$1.53 +0.01 (+0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$1.53 0.00 (0.00%)

As of 04:04 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

TransCode Therapeutics NASDAQ:RNAZ

$11.51 +0.52 (+4.73%)

Closing price 04:00 PM Eastern

Extended Trading

$11.20 -0.31 (-2.70%)

As of 07:23 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Sol-Gel Technologies NASDAQ:SLGL

$15.25 -0.95 (-5.86%)

Closing price 04:00 PM Eastern

Extended Trading

$15.08 -0.16 (-1.08%)

As of 04:40 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time